The Week Ahead: Hom...
Health Care: Drugs
Progenics Pharmaceuticals Inc. (PGNX: NASDAQ)
$4.31 0.18 | 4.36%
05/17/13 - 04:00 PM ET
Growth Rates
| GROWTH RATES |
|---|
| REVENUE (Trailing 12 Quarters) |
| EARNINGS PER SHARE (Trailing 12 Quarters) |
| DIVIDENDS (Trailing 12 Quarters) |
Portfolios with PGNX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorDrugs Facing FDA Approval i...
- UserGFNN Stockdiagnostics 14
- ContributorStocks Rising On Unusual Vo...
- ProTudor Investment
- ContributorStocks At New 52-Week Highs...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks At New 52-Week Highs...
Latest PGNX Headlines from TheStreet
- Progenics Pharmaceuticals Added To The NASDAQ Biotechnology Index 05.17.13 | 05:05 pm
- Progenics Pharmaceuticals Announces First Quarter 2013 Financial Results 05.10.13 | 07:05 am
- Progenics Pharmaceuticals To Host Conference Call To Review First Quarter 2013 Financial Results On May 10 05.06.13 | 05:05 pm
- Short Interest Moves 19% Higher For PGNX 04.25.13 | 04:04 pm
- Progenics Pharmaceuticals To Present At Needham Healthcare Conference 04.24.13 | 05:04 pm
- 'Mad Money' Lightning Round: I Like Priceline 04.02.13 | 06:04 am
- Cramer's 'Mad Money' Recap: Checking My List 04.01.13 | 07:04 pm
- Progenics Pharmaceuticals Announces Fourth Quarter And Year-End 2012 Financial Results 03.15.13 | 07:03 am
- Progenics Pharmaceuticals To Host Conference Call To Review Fourth Quarter Financial Results On March 15 03.08.13 | 03:03 pm
- 5 Stocks Under $10 Set to Soar 03.07.13 | 01:03 pm
Press Releases for PGNX
- MedImmune Announces Agreement With Progenics Pharmaceuticals To Develop Therapies Against Serious Bacterial Infections - PR Newswire 12.17.12 | 09:12 am
- Salix And Progenics Receive Complete Response Letter From FDA For RELISTOR® SNDA - Business Wire 07.27.12 | 07:07 pm
- Salix And Progenics Announce Positive Highly Statistically Significant Results Of Oral Methylnaltrexone For Phase 3 Trial In Chronic, Non-Cancer Pain Subjects With Opioid-Induced Constipation - Business Wire 12.20.11 | 07:12 am
- Progenics And Salix Announce FDA Acceptance Of SNDA Filing For RELISTOR® In Patients With Non-Cancer Pain - Business Wire 08.30.11 | 07:08 am
- Progenics Pharmaceuticals To Webcast Upcoming Presentations - Business Wire 04.04.11 | 08:04 am
- Progenics Pharmaceuticals Announces Fourth Quarter And Year-End 2010 Financial Results - Business Wire 03.15.11 | 08:03 am
- Progenics Pharmaceuticals Announces Changes In Executive Responsibilities - Business Wire 03.09.11 | 07:03 am
- Progenics Reports Positive Preliminary Data From Ongoing Phase 1 Clinical Study Of PSMA ADC - Business Wire 02.17.11 | 04:02 pm
- Salix Pharmaceuticals And Progenics Pharmaceuticals Announce Worldwide License Agreement For RELISTOR® - Business Wire 02.07.11 | 07:02 am
- Progenics Pharmaceuticals And Salix Pharmaceuticals Announce Worldwide License Agreement For RELISTOR® - Business Wire 02.07.11 | 07:02 am
Partner Headlines for PGNX
- 5 Healthcare Companies With Recent Insider Buying - Seeking Alpha 11.18.12 | 09:11 am
- 5 Stocks That Dropped the Most Since Gurus Bought Them - NASDAQ 09.13.12 | 07:09 pm
- Another Delay for Salix Candidate - Analyst Blog - NASDAQ 09.10.12 | 10:09 pm
- Another Delay for Salix Candidate - Analyst Blog - Zacks 09.10.12 | 06:09 pm
- Stock Futures Mixed; Salix, Progenics Tumble - Investor's Business Daily 07.30.12 | 09:07 am
- Positive Data on Theravance Drug - Analyst Blog - Zacks 07.11.12 | 06:07 pm
- The Zacks Analyst Blog Highlights: US Airways Group, United Continental Holdings, Delta Airlines, Salix Pharmaceuticals and Progenics Pharmaceuticals - Press Releases - Zacks 04.24.12 | 09:04 am
- What's It Going To Take To Get Salix Cheap? - Seeking Alpha 02.29.12 | 08:02 am
- Progenics Should Outperform The Market In The Short Term - Seeking Alpha 02.15.12 | 08:02 am
- Biotech Stocks To Watch In 2012 - Seeking Alpha 02.06.12 | 09:02 am
